GSTM1 and Thrombocytopenia: Neutropenia was the most common side effect (90%) and was in most cases grade 3 and 4, followed by anemia (Hb < 11 g/dL) and thrombocytopenia (<100 × 109/L) that were observed in 85% and 67.5%, respectively.